Background: Microglia are the endogenous immune cells of the brain and act as sensors of pathology to maintain brain homeostasis and eliminate potential threats. In Alzheimer's disease (AD), toxic amyloid beta (Aβ) accumulates in the brain and forms stiff plaques. In late-onset AD accounting for 95% of all cases, this is thought to be due to reduced clearance of Aβ. Human genome-wide association studies and animal models suggest that reduced clearance results from aberrant function of microglia. While the impact of neurochemical pathways on microglia had been broadly studied, mechanical receptors regulating microglial functions remain largely unexplored. Methods: Here we showed that a mechanotransduction ion channel, PIEZO1, is expressed and functional in human and mouse microglia. We used a small molecule agonist, Yoda1, to study how activation of PIEZO1 affects AD-related functions in human induced pluripotent stem cell (iPSC)-derived microglia-like cells (iMGL) under controlled laboratory experiments. Cell survival, metabolism, phagocytosis and lysosomal activity were assessed using real-time functional assays. To evaluate the effect of activation of PIEZO1 in vivo, 5-month-old 5xFAD male mice were infused daily with Yoda1 for two weeks through intracranial cannulas. Microglial Iba1 expression and Aβ pathology were quantified with immunohistochemistry and confocal microscopy. Published human and mouse AD datasets were used for in-depth analysis of PIEZO1 gene expression and related pathways in microglial subpopulations. Results: We show that PIEZO1 orchestrates Aβ clearance by enhancing microglial survival, phagocytosis, and lysosomal activity. Aβ inhibited PIEZO1-mediated calcium transients, whereas activation of PIEZO1 with a selective agonist, Yoda1, improved microglial phagocytosis resulting in Aβ clearance both in human and mouse models of AD. Moreover, PIEZO1 expression was associated with a unique microglial transcriptional phenotype in AD as indicated by assessment of cellular metabolism, and human and mouse single-cell datasets. Conclusion: These results indicate that the compromised function of microglia in AD could be improved by controlled activation of PIEZO1 channels resulting in alleviated Aβ burden. Pharmacological regulation of these mechanoreceptors in microglia could represent a novel therapeutic paradigm for AD.
Stroke is one of the leading causes of death worldwide and currently only few therapeutic options are available. Stroke is a sexually dimorphic disease contributing to the difficulty in finding efficient treatments. Poststroke neuroinflammation is geared largely by brain microglia and infiltrating peripheral immune cells and largely contributes to sex differences in the outcome of stroke. Microglia, since very early in the development, are sexually divergent, imprinting specific sex-related features. The diversity in terms of microglial density, morphology, and transcriptomic and proteomic profiles between sexes remains in the adulthood and is likely to contribute to the observed sex-differences on the postischemic inflammation. The impact of sexual hormones is fundamental: changes in terms of risk and severity have been observed for females before and after menopause underlining the importance of altered circulating sexual hormones. Moreover, aging is a driving force for changes that interact with sex, shifting the inflammatory response in a sex-dependent manner. This review summarizes the present literature on sex differences in stroke-induced inflammatory responses, with the focus on different microglial responses along lifespan.
Background: Areas of selective neuronal loss (SNL) represent the first morphological signs of damage in the penumbra region and are considered putative targets for ischemic stroke therapy. Here we performed a novel assessment of measuring the effects of the anti-inflammatory agent, celecoxib, analyzing simultaneously the different neural populations (neurons, astrocytes and microglia cells) in SNL and non-SNL areas. Methods: Rats were subjected to 1 hour of middle cerebral artery occlusion (MCAO) and treated with celecoxib 1 h and 24 h after ischemia. Infarct volume measurements and triple immunostaining of neurons (NeuN), microglia (IBA I) and astroglia (GFAP) were performed after 12 h and 48 h of reperfusion. Motor response was tested by standard behavioural assays at 3 h, 12 h, 24 h and 48 h. Results: Confocal analysis revealed that the percentage of SNL areas, microglia densities and glial activation increased at 48 h of reperfusion. Celecoxib treatment improved the neurological deficit, reduced the infarct volume by 50% after 48 h of reperfusion, and resulted in a reduced percentage of SNL areas and microglia and astroglia reactivity after 48 h of reperfusion. Conclusions: This study proves for the first time that celecoxib presents post-ischemic neuroprotective effects in a transient MCAO model, prevents, or delays, the presence of SNL areas and reduces glial activation.
1 September 2017 in Biochimica et Biophysica Acta (BBA) - Biomembranes